Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Eagle Asset Management Inc.

Eagle Asset Management Inc. increased its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 130.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 624,759 shares of the biopharmaceutical company’s stock after acquiring an additional 353,723 shares during the quarter. Eagle Asset Management Inc.’s holdings in Intra-Cellular Therapies were worth $45,714,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Summit Securities Group LLC acquired a new position in shares of Intra-Cellular Therapies during the 2nd quarter valued at about $56,000. Capital Performance Advisors LLP acquired a new position in Intra-Cellular Therapies in the third quarter valued at about $74,000. CWM LLC lifted its position in Intra-Cellular Therapies by 83.9% in the second quarter. CWM LLC now owns 1,372 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 626 shares during the last quarter. Covestor Ltd lifted its position in Intra-Cellular Therapies by 40.4% in the third quarter. Covestor Ltd now owns 1,811 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 521 shares during the last quarter. Finally, Assetmark Inc. lifted its position in Intra-Cellular Therapies by 9.1% in the third quarter. Assetmark Inc. now owns 2,477 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 207 shares during the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Trading Up 0.3 %

Shares of NASDAQ:ITCI opened at $85.69 on Friday. The firm’s 50-day moving average is $79.05 and its two-hundred day moving average is $74.66. Intra-Cellular Therapies, Inc. has a 1 year low of $58.14 and a 1 year high of $93.45.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The firm had revenue of $175.40 million for the quarter, compared to analysts’ expectations of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm’s quarterly revenue was up 39.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.25) earnings per share. As a group, research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Insider Activity at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 40,513 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $73.58, for a total value of $2,980,946.54. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at approximately $78,754,807.82. This represents a 3.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Michael Halstead sold 22,869 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total value of $2,038,085.28. The disclosure for this sale can be found here. Insiders sold 97,778 shares of company stock valued at $7,524,436 over the last three months. 2.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ITCI shares. Morgan Stanley upped their target price on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. The Goldman Sachs Group decreased their target price on shares of Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. UBS Group decreased their target price on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. JPMorgan Chase & Co. upped their target price on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a research report on Monday, November 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 target price on shares of Intra-Cellular Therapies in a research report on Monday, September 16th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Intra-Cellular Therapies presently has an average rating of “Moderate Buy” and a consensus price target of $97.23.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.